All posts by PIER MARIA FORNASARI

PIER MARIA FORNASARI
2023-05-05

New Build Better Bones online platform to support people with osteoporosis and their caregivers 

The new International Osteoporosis Foundation (IOF) platform provides easy-to-follow exercise guidance and nutritional tips to benefit bone health, alerts to falls safety hazards in the home, and provides helpful information for caregivers.  The International Osteoporosis Foundation (IOF) has launched the Build Better Bones platform, a new online resource that provides people with osteoporosis, and their caregivers, with

Read More

No Comments InWELLNESS
PIER MARIA FORNASARI
2023-05-05

Machine learning links unresolving secondary pneumonia to mortality in COVID-19 patients with severe pneumonia.

Secondary bacterial pneumonia that does not resolve was a key driver of death in patients with Covid, according to a study. The study was published in the Journal of Clinical Investigation. The scientists also found evidence that Covid does not cause a “cytokine storm”, so often believed to cause death. Secondary bacterial pneumonia that does

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2023-04-26

FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene

Action FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). Qalsody is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. The approval was based on a reduction in plasma neurofilament light (NfL), a blood-based

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2023-04-17

FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2023-04-17

More than 1 million lives saved in Europe by COVID-19 vaccines since the end of 2020: research presented at European Congress of Clinical Microbiology & Infectious Diseases

COVID-19 vaccination directly saved at least 1,004,927 lives across Europe between December 2020 and March 2023, according to new research being presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark (15-18 April). The new estimates by WHO/Europe and presented at the conference by Dr Margaux Meslé,  Epidemiologist at

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2023-04-13

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

A nonstatin therapy approved almost 3 years ago to treat low-density lipoprotein (LDL) cholesterol also cuts the risk of major cardiovascular events, especially heart attacks, according to data presented. Bempedoic acid, approved in February 2020 as Nexletol (Esperion), reduced by 13% the risk of a 4-part composite end point of major adverse cardiovascular events (MACE),

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2023-04-13

New therapy harnesses patients’ blood cells to fight tumors

Noninvasive approach is fast, cost-effective and could be used to treat a variety of cancers doptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2023-04-13

Severe Covid-19: new anti-C5a antibody approved by FDA

A new antibody drug by pharmaceutical company inflaRx received FDA emergency use authorization to treat critically ill Covid-19 patients. One of the greatest hurdles for monoclonal antibody development during the Covid-19 pandemic is the ongoing mutation of the SARS-CoV-2 virus. Most antibodies introduced throughout the pandemic targeted the virus spike protein, which mutates significantly with every emerging

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2023-03-30

Transcatheter Arterialization of Deep Veins in Chronic Limb-Threatening Ischemia can avoid amputation

A study published in the New England Journal of Medicine has shown that there may finally be an alternative to amputation for patients suffering from chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease. This study, co-led by University Hospitals (UH) Harrington Heart & Vascular Institute, could lead to the first FDA approval of

Read More

One comment InRESEARCH